You are here: Home

iSi Health

iSi health

iSi Health will foster the community of KU Leuven and UZ Leuven researchers contributing to the development and implementation of multi-scale, physics-based modeling approaches for personalized health. As such, the institute will accelerate the adoption of in silico medicine and in particular leverage and prepare the integration of in silico medical device testing, drug performance evaluation and in silico clinical trials. ISi Health has the explicit ambition to position KU Leuven and UZ Leuven at the forefront of this paradigm shift and take a leading role in conceptualising this healthcare of the future.
 
With iSi Health, we will provide a platform for interdisciplinary knowledge exchange and expertise building across research domains and groups, optimally preparing for the ‘to be expected’ impact of in silico techniques in the medical domain.
 
In order to achieve this mission, different actions are identified:

  • Bring together the significant yet fragmented community of researchers at KU Leuven and UZ Leuven that are already contributing to this field and expressed their interest in participating;
  • Provide a platform for interdisciplinary knowledge exchange and facilitate expertise building across research domains and groups,
  • Take an internationally leading role ineffective health data integration solutions through provision of verified and validated data-driven and physics-based computational tools for healthcare,
  • Launch concerted research activities on development approval, acceptance, socioeconomic impact and legal integration of in silico techniques, and
  • Prepare blue-prints for educational action programmes, creating the workforce of the future that holds essential multi-disciplinary skills from a unique background of integrated biomedical, medical and engineering expertise.

 
By these concerted research and networking activities, we aim to amplify unique expertise currently dispersed across research groups in KU Leuven and UZ Leuven. By structurally bringing together engineering, (para)medical and pharmaceutical disciplines we will leverage clinical and economical valorization, whereas cross-fertilisation with econosocio- legal disciplines will optimally prepare for real-life implementation of in silico approaches in the healthcare system of the future. Additionally, through dedicated information actions to relevant national and international clinical, industrial
and governmental stakeholders, we aim to truly impact current rules of practice within the biomedical industry worldwide and leverage on national but also European policy.


Through the Leuven Institute for in silico health, KU Leuven together with UZ Leuven will be prepared to take a leap start in conceptualising, designing and conducting in silico trials, medical device testing and drug performance evaluation, thereby leading healthcare innovation in Europe and worldwide.

Read the interview given at the kick-off meeting on december 19th, 2022.

More information will follow soon.

Contact person: Ilse Jonkers 

Back